UBS AM
STOK icon

UBS AM’s Stoke Therapeutics STOK Stock Holding History

UBS AM’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.13M Buy
65,228
+7,043
+12% +$226K ﹤0.01% 2019
2026
Q1 		$1.89M Buy
58,185
+973
+2% +$31.9K ﹤0.01% 2066
2025
Q4 		$1.82M Sell
57,212
-18,646
-25% -$561K ﹤0.01% 1925
2025
Q3 		$1.78M Sell
75,858
-31,382
-29% -$538K ﹤0.01% 1804
2025
Q2 		$1.22M Buy
107,240
+24,438
+30% +$232K ﹤0.01% 2341
2025
Q1 		$551K Sell
82,802
-12,703
-13% -$118K ﹤0.01% 2484
2024
Q4 		$1.05M Buy
95,505
+52,813
+124% +$649K ﹤0.01% 2337
2024
Q3 		$525K Sell
42,692
-14,707
-26% -$208K ﹤0.01% 2632
2024
Q2 		$775K Buy
+57,399
New +$775K ﹤0.01% 2489
2023
Q4 		– Sell
-11,398
Closed -$44.9K – 2600
2023
Q3 		$44.9K Hold
11,398
– – ﹤0.01% 2582
2023
Q2 		$94.9K Hold
11,398
– – ﹤0.01% 2645
2023
Q1 		$94.9K Buy
+11,398
New +$103K ﹤0.01% 2645

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM's STOK Position: Q2 2026 in Review

UBS AM increased its Stoke Therapeutics (STOK) stake by 12% in Q2 2026, buying an estimated $226K and bringing the position to 65,228 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2019.

UBS AM first reported a position in STOK in Q1 2023 and has held it in 12 quarters since. 198 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • UBS AM held 65,228 shares of Stoke Therapeutics worth $2.13M as of Q2 2026.
  • UBS AM bought 7,043 Stoke Therapeutics shares in Q2 2026, an estimated $226K.
  • Stoke Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2019 holding.
  • UBS AM first reported a position in Stoke Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • 198 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.